DK1611252T3 - In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren - Google Patents
In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blærenInfo
- Publication number
- DK1611252T3 DK1611252T3 DK04723215T DK04723215T DK1611252T3 DK 1611252 T3 DK1611252 T3 DK 1611252T3 DK 04723215 T DK04723215 T DK 04723215T DK 04723215 T DK04723215 T DK 04723215T DK 1611252 T3 DK1611252 T3 DK 1611252T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell carcinoma
- vitro method
- transitional cell
- bladder
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200300708 | 2003-03-26 | ||
PCT/EP2004/003219 WO2004085676A1 (fr) | 2003-03-26 | 2004-03-25 | Methode de detection in vitro du carcinome a cellules transitionnelles de la vessie |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1611252T3 true DK1611252T3 (da) | 2009-11-23 |
Family
ID=33041266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04723215T DK1611252T3 (da) | 2003-03-26 | 2004-03-25 | In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren |
Country Status (7)
Country | Link |
---|---|
US (1) | US8124331B2 (fr) |
EP (1) | EP1611252B1 (fr) |
AT (1) | ATE437963T1 (fr) |
DE (1) | DE602004022266D1 (fr) |
DK (1) | DK1611252T3 (fr) |
ES (1) | ES2330634T3 (fr) |
WO (1) | WO2004085676A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
US9089601B2 (en) * | 2006-07-10 | 2015-07-28 | University Of Rochester | Pre- and intra-operative imaging of bladder cancer |
ES2323927B1 (es) * | 2007-03-30 | 2010-05-14 | Laboratorios Salvat, S.A. | Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga. |
EP2313435A4 (fr) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3) |
SG174904A1 (en) | 2009-03-25 | 2011-11-28 | Genentech Inc | Anti-fgfr3 antibodies and methods using same |
EP2877209A1 (fr) * | 2012-07-27 | 2015-06-03 | Genentech, Inc. | Méthodes de traitement d'états associés à fgfr3 |
AU2013320972B2 (en) * | 2012-09-27 | 2018-08-30 | Chugai Seiyaku Kabushiki Kaisha | FGFR3 fusion gene and pharmaceutical drug targeting same |
HUE058219T2 (hu) * | 2014-09-26 | 2022-07-28 | Janssen Pharmaceutica Nv | FGFR-mutánsgénpanel alkalmazása olyan rákbetegek azonosításában, akik FGFR-inhibitorral történõ kezelésre reszponzívak lesznek |
JP2019528460A (ja) | 2016-08-05 | 2019-10-10 | ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク | 膀胱がんのバイオマーカーとしてのケラチン17 |
MX2023002106A (es) | 2020-08-21 | 2023-03-15 | Genzyme Corp | Anticuerpos fgfr3 y metodos de uso. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030087854A1 (en) * | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
ES2280218T5 (es) | 1999-05-05 | 2010-05-14 | Institut Curie | Medios de deteccion y tratamiento de patologias asociadas a fgfr3. |
WO2002102972A2 (fr) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Anticorps bloquant l'activation d'un recepteur a activite proteine tyrosine kinase, procedes de criblage et utilisations associes |
-
2004
- 2004-03-25 ES ES04723215T patent/ES2330634T3/es not_active Expired - Lifetime
- 2004-03-25 AT AT04723215T patent/ATE437963T1/de not_active IP Right Cessation
- 2004-03-25 WO PCT/EP2004/003219 patent/WO2004085676A1/fr active Application Filing
- 2004-03-25 DK DK04723215T patent/DK1611252T3/da active
- 2004-03-25 DE DE602004022266T patent/DE602004022266D1/de not_active Expired - Lifetime
- 2004-03-25 EP EP04723215A patent/EP1611252B1/fr not_active Expired - Lifetime
- 2004-03-25 US US10/550,608 patent/US8124331B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2330634T3 (es) | 2009-12-14 |
EP1611252A1 (fr) | 2006-01-04 |
ATE437963T1 (de) | 2009-08-15 |
US20070092878A1 (en) | 2007-04-26 |
DE602004022266D1 (de) | 2009-09-10 |
WO2004085676A1 (fr) | 2004-10-07 |
EP1611252B1 (fr) | 2009-07-29 |
US8124331B2 (en) | 2012-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gu et al. | MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells | |
Woodcock et al. | The treatment of idiopathic pulmonary fibrosis | |
BR0308290A (pt) | Tratamento e prevenção de distúrbios inflamatórios | |
NO20044462L (no) | Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer | |
AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
SG10201809111XA (en) | The use of inhibitors of bruton's tyrosine kinase (btk) | |
ATE547420T1 (de) | Azepinoindol und pyridoindolderivate als pharmazeutische mittel | |
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
BRPI0810336A2 (pt) | "método para tratar e/ou prevenir úlceras de pele em um indivíduo" | |
MX2011006091A (es) | Inhibidores de imidazopirazina syk. | |
ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
NO20052923L (no) | Fusjonerte bicykliske nitrogeninneholdende heteroringer | |
CO6390109A2 (es) | Inhibidores de syk de imidazopirazina | |
AR058126A1 (es) | Antagonistas y conjugados del peptido cgrp | |
EA200400966A1 (ru) | Новые лекарственные формы замещенного бензимидазола и способ их применения | |
UA88440C2 (ru) | ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β | |
NO20072931L (no) | Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva | |
ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
DK1611252T3 (da) | In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren | |
DE60125417D1 (de) | Verminderung der nebenwirkungen der chemotherapie in krebspatienten | |
MA37777B1 (fr) | Préparation pharmaceutique | |
BR112023020219A2 (pt) | Anticorpos anti-il-2r agonistas e métodos de uso | |
SV2008002856A (es) | 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas | |
MX2009001070A (es) | Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. |